Treatment Resistant Depression Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) - Estimates DelveInsight | Merck, Navitor, GH Research, Novartis, Relmada Therapeutics, Alkermes, AbbVie, Janssen, Celon Pharma, ACADIA Pharma

As per DelveInsight, the Treatment Resistant Depression Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Treatment-Resistant Depression and the launch of novel therapies in the market.

DelveInsight's "Treatment Resistant Depression Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Treatment Resistant Depression Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Treatment Resistant Depression therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Treatment Resistant Depression treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Treatment Resistant Depression: An Overview
Treatment-resistant Depression (TRD) typically refers to inadequate response to at least one antidepressant trial of adequate doses and duration. TRD is a relatively common occurrence in clinical practice, with up to 50-60% of the patients not achieving adequate response following antidepressant treatment.

TRD is usually linked to higher rates of comorbidity, particularly with other psychiatric disorders, chronic pain, and fibromyalgia. On the other hand, the impact of both physical and psychiatric illness comorbidities is much higher among TRD patients. Some environmental factors related to TRD are lower socioeconomic status, non-supportive social environment, family conflicts, chronic stressors, multiple loss events, lower level of education, and social support and work dysfunction.

Treatment Resistant Depression Market Key Facts
• The total Treatment-Resistant Depression market size in the 7MM was approximately USD 3,100 million in 2022 and is projected to increase during the forecast period (2023-2032).
• In 2022, the US captured the highest market share (84%), followed by Germany (5%), out of all the 7MM countries.
• The UK accounted for a market size of USD 110 million in 2022. The market size is further expected to increase during the forecast period.
• In Japan, the Treatment-Resistant Depression market size is expected to increase at a CAGR of 2% during the forecast period (2023-2032).
• The total diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM were approximately 6,409,000 cases in 2022 and are projected to increase during the forecast period (2023-2032).
• Among the EU4 countries, Germany accounted for the highest number of total diagnosed prevalent cases of Treatment-Resistant Depression, whereas Italy accounted for the lowest number of cases in 2022.

Get a Detailed Overview of the Evolving Treatment Resistant Depression Market Trends @
https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Treatment Resistant Depression Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Treatment Resistant Depression therapies in the market. It also provides a detailed assessment of the Treatment Resistant Depression market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Treatment Resistant Depression drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Treatment Resistant Depression Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Treatment Resistant Depression Epidemiology
The epidemiology section covers detailed insights into the historical, and current Treatment Resistant Depression patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Treatment Resistant Depression Epidemiology Segmented as -
• Total Diagnosed Prevalent Cases of Treatment-Resistant Depression
• Gender-specific Cases of Treatment-Resistant Depression
• Age-specific Cases of Treatment-Resistant Depression

Treatment Resistant Depression Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Treatment Resistant Depression market or expected to be launched during the study period. The analysis covers the market share by Treatment Resistant Depression drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Treatment Resistant Depression Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Treatment Resistant Depression Market @
https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Treatment Resistant Depression Therapeutics Assessment
Pharmacologic treatment options include switching, combination, and potentiation strategies among commonly used antidepressant drugs. Most of the available antidepressants, such as selective serotonin reuptake inhibitors (SSRI), dual serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, agomelatine, tianeptine are used to treat TRD.

The US FDA has approved two therapies for TRD. It includes Eli Lilly's SYMBYAX, an olanzapine and fluoxetine combination, approved in 2009 for the acute treatment of TRD and Johnson & Johnson's SPRAVATO, an intranasal esketamine, approved in 2019, for use in conjunction with an oral antidepressant in adults with TRD.

Various nonpharmacological therapies are also recommended, including electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), and vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy involve majorly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT).

Unmet needs like the lack of universal diagnostic criteria for "TRD," lack of real-time TRD epidemiological studies, and the ready availability of traditional antidepressant generics hamper the market's growth. Further, due to the increasing prevalence of depression, the increasing treatment rate of mental illness, resistance to available drugs is increasing. There is a need for more effective treatments.

Several major pharma and biotech companies are actively engaged in developing therapies for the Treatment of Resistant Depression. The pipeline for TRD is robust and includes MK-1942 (Merck/Novamind), Esketamine DPI (Celon Pharma), Psilocybin (COMPASS Pathways), MIJ821 (Novartis), NV-5138 (Navitor Pharmaceuticals/Supernus Pharmaceuticals), DB104 (Denovo Biopharma) and BPL-003 (Beckley Psytech), among others. Notably, among these companies, Axsome Therapeutics has positioned itself as a key player with Treatment-Resistant Depression drug candidates progressing to the most advanced stage, namely preregistration. The involvement of numerous key companies highlights the collaborative efforts within the pharmaceutical industry to advance innovative treatments for individuals affected by this complex mental health condition.

Due to a robust pipeline equipped with high-priced therapies on one side and a dynamic market space with increasing pressure from payers and limitations in evidence development on the other, market access strategies become all the more important for a successful market launch in TRD.

Leading Companies in the Treatment Resistant Depression Therapeutics Market Include
Some of the key companies in the Treatment Resistant Depression Therapeutics Market include Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, AITAi Life Sciences, and others.

Emerging and Marketed Treatment Resistant Depression Therapies Covered in the Report Include
• AXS-05: Axsome Therapeutics
• MIJ821: Novartis
• COMP360 (Psilocybin): COMPASS Pathways
• NV-5138- Navitor Pharmaceuticals/Supernus Pharmaceuticals
• DB104: Denovo Biopharma
• MK-1942: Merck & Co.
• BPL-003: Beckley Psytech
• MIJ821: Novartis
And Many Others

Learn More About the Emerging Therapies and key Companies in the Treatment Resistant Depression Therapeutics Market @
https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Treatment Resistant Depression Competitive Intelligence Analysis
4. Treatment Resistant Depression Market Overview at a Glance
5. Treatment Resistant Depression Background and Overview
6. Treatment Resistant Depression Patient Journey
7. Treatment Resistant Depression Epidemiology and Patient Population
8. Treatment Resistant Depression Treatment Algorithm, Current Treatment, and Medical Practices
9. Treatment Resistant Depression Unmet Needs
10. Key Endpoints of Treatment Resistant Depression Treatment
11. Treatment Resistant Depression Marketed Products
12. Treatment Resistant Depression Emerging Therapies
13. Treatment Resistant Depression Seven Major Market Analysis
14. Attribute Analysis
15. Treatment Resistant Depression Market Outlook (7 major markets)
16. Treatment Resistant Depression Access and Reimbursement Overview
17. KOL Views on the Treatment Resistant Depression Market.
18. Treatment Resistant Depression Market Drivers
19. Treatment Resistant Depression Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.